In conclusion, the application of a targeted assay using next‐generation sequencing of FFPE samples allowed the identification both somatic and germline BRCA1/2 mutations in a group of patients with serous ovarian tumors. The gene discussed is BRCA1; the disease is ovarian serous tumor.